Asston Pharmaceuticals IPO Subscribed 1.75x on Day 1

Asston Pharmaceuticals IPO subscribed over 1.75x on its First day of subscription, wherein QIB subscribed 3.51x, NII subscribed 0.66, and RII subscribed 1.22x.

Asston Pharmaceuticals’s IPO subscription started on Wednesday, July 9, 2025, and will close on July 11, 2025, as per the schedule. The price band is set at ₹115 to ₹123 per share with a face value of ₹10.

Asston Pharmaceuticals IPO Subscription Status

Asston Pharmaceuticals IPO subscribed over 1.75x on its First day till 05.00 PM on 9th July 2025.

Asston Pharmaceuticals IPO subscription QIB investors portion is 3.51x times, while NII subscribed 0.66x times, and RII investors subscribed 1.22x times.
The company has received bids for 26,15,000 shares against 14,93,000 shares on offer on the First day.
Asston Pharmaceuticals IPO subscribed over 1.75x times on day 1.

About Asston Pharmaceuticals IPO

Asston Pharmaceuticals Limited was established in 2019 is one of the growing companies engaged in the business of pharmaceuticals, as well as involved in the exporting of the healthcare products globally. The company’s portfolio consists of wide range of products such as tablets, capsules, sachets, and syrups. The company offers various products in therapeutic categories include analgesics, antibiotics, antifungals, vitamins, and more. Asston pharmaceutical is involved in the manufacturing of pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis mostly working on a principle-to-principle approach with various marketers. Asston pharmaceuticals ltd is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing. The company’s portfolio consists of many products such as Albendazole USP 400 mg, Diclofenac 100 mg, Ibuprofen, paracetamol, and Ferrovit Syrup. The company includes 46 Permanent employees and 6 contractual employees as of 3 July, 2025.

Asston Pharmaceuticals IPO Company Financial Report

The company reported revenue of ₹25.61 crores in 2025 against ₹15.84 crores in 2024. The company reported a profit of ₹4.33 crores in 2025 against a profit of ₹1.36 crores in 2024.

Asston Pharmaceuticals IPO GMP

Asston Pharmaceuticals IPO GMP was ₹15 as of Wednesday, 9th July. That indicates the IPO is trading at ₹138 with a ₹15 premium in the grey market against the issue price of ₹123.

Jagat Joshi

An experienced stock market professional with expertise in IPO research, market insights, and equity strategies. With a strong background in research and capital markets, he delivers comprehensive coverage on upcoming IPOs, subscription patterns, grey market premium (GMP), and post-listing performance, along with detailed reviews, recommendations, and technical analysis.

Add IPOWatch to your Google News feed.

Disclaimer: This content is provided strictly for educational and informational purposes. The securities or investments mentioned are not to be considered as investment advice or recommendations. The Investors are advised to do their own research or connect with a financial advisor before making any investment decisions.